Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.39 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.39 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.39 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283374 | 0.88 | CRHR1 (0.71) | CRHR1ADORA3CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL6281208 | 0.86 | CRHR1 (0.60) | CRHR1CYP1A1CYP1B1CYP1A2CYP2E1 | |
| SCHEMBL6284889 | 0.85 | CRHR1 (0.59) | CRHR1ADORA3CYP1A1CYP1B1CACNA2D1 | |
| SCHEMBL6287127 | 0.83 | CRHR1 (0.60) | CRHR1ADORA3CYP1A1CYP1B1CACNA2D1 | |
| SCHEMBL6286536 | 0.82 | CRHR1 (0.57) | CRHR1ADORA3CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL6346153 | 0.82 | CRHR1 (0.65) | CRHR1ADORA3CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL6285778 | 0.82 | CRHR1 (0.59) | CRHR1CYP1A1CYP1B1CACNA2D1CYP1A2 | |
| SCHEMBL6281216 | 0.81 | CRHR1 (0.58) | CRHR1ADORA3CYP1A1CYP1B1CACNA2D1 | |
| SCHEMBL5412011 | 0.80 | CRHR1 (0.66) | CRHR1ADORA3CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL5412053 | 0.80 | CRHR1 (0.62) | CRHR1ADORA3CYP1A1CYP1B1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176721-A1 | 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines | HUANG JIANHUA (US) | 2005-08-11 | — | — | US | claimed |
| JP-2005500286-A | — | — | 2005-01-06 | — | — | JP | claimed |
| EP-1399428-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-03-24 | — | — | EP | claimed |
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | NEUROGEN CORPORATION | 2003-06-26 | — | — | US | claimed |
| WO-2002100838-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| US-20050176721-A1 | 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines | HUANG JIANHUA (US) | 2005-08-11 | — | — | US | disclosed |
| US-6887875-B2 | Bind with high selectivity and/ or high affinity to CRF1 receptors (Corticotropin Releasing Factor 1 Receptors), useful for treating psychiatric and neurological diseases, including depression, anxiety and post trauma stress | NEUROGEN CORPORATION (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1399428-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | NEUROGEN CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2002100838-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | CRHR2, CRHR1, CRH | CRHR1 2/4885ADORA3 488/4885CYP1A1 1960/4885 |
| US-20050176721-A1 | 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines | CRHR2, CRHR1, CRH | CRHR1 2/4885ADORA3 560/4885CYP1A1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.